Granted Patent B2

US 10,072,298 · App. 14/672,066 · Granted Sep 11, 2018

Inventors: Daniel Rhodes (Ann Arbor, MI); Seth Sadis (Ann Arbor, MI); Peter Wyngaard (Ann Arbor, MI); Nikolay Khazanov (Ann Arbor, MI); Santhoshi Bandla (Northville, MI); Mark Tomilo (Ann Arbor, MI); Sean Eddy (Ann Arbor, MI); Emma Bowden (Ann Arbor, MI); Jia Li (Northville, MI)

Assignee: LIFE TECHNOLOGIES CORPORATION

C12Q1/6886C12Q2600/156C12Q2600/158C12Q2600/16G06F19/18G06F19/22G06F19/24

Abstract

Claims (13)

1. A method of detecting a CEP85L-ROS1 gene fusion in a sample from a subject, the method comprising:

generating a reaction mixture comprising nucleic acid from the sample and a pair of primers that specifically hybridize to a target nucleic acid comprising the sequence of SEQ ID NO:17 , wherein the sample comprises the target nucleic acid;

amplifying the target nucleic acid using the pair of primers, thereby producing amplicons;

sequencing the amplicons; and

detecting the presence of a CEP85L-ROS1 gene fusion comprising the sequence of SEQ ID NO:17 in the sequenced amplicons.

2. The method of claim 1 , further comprising diagnosing the subject as having glioblastoma and determining a treatment based on the CEP85L-ROS1 gene fusion detected in the sample.

3. The method of claim 2 , wherein the treatment is crizotinib.

4. The method of claim 1 , wherein the sample is a blood sample.

5. The method of claim 1 , wherein the sample is a tissue sample.

6. The method of claim 5 , wherein the sample is a formalin-fixed, paraffin-embedded sample.

7. The method of claim 1 , wherein the sample comprises tumor tissue.

8. The method of claim 7 , wherein the tumor is a glioblastoma.

9. The method of claim 1 , wherein the sequencing is by next generation sequencing technology.

Assignments (1)

Continuity (14)